Siemens Healthineers and Novo Partnered on Liver Test
The companies are collaborating to improve the detection of MASLD and MASH for patients across the U.S.
Updated on Sept. 21, 2026 in Diabetes
Live Poll
Do you believe medical companies should prioritize blood tests over traditional biopsy for early diagnosis?
Siemens Healthineers and Novo have teamed up to build awareness for metabolic dysfunction-associated steatotic liver disease (MASLD). The partnership focuses on utilizing diagnostic testing to support earlier diagnosis and treatment access for those with progressive liver conditions.
Why it matters
Current methods for identifying liver fibrosis often rely on invasive biopsies or specialized imaging, which create significant barriers for patients. This collaboration aims to streamline the diagnostic process, helping clinicians identify patients who may benefit from approved therapeutic options.
A national health figure indicates that MASLD affects approximately 25% of the U.S. adult population. The diagnostic approach relies on the Enhanced Liver Fibrosis test, which received FDA de novo clearance in 2021.
The players
Siemens Healthineers
A global medical technology company providing diagnostic imaging and laboratory testing equipment, including the Atellica immunoassay platform.
Novo
A pharmaceutical company focused on metabolic diseases and diabetes, recently granted FDA approval for Wegovy as a treatment for MASH.
The details
The Enhanced Liver Fibrosis test functions on Atellica immunoassay systems to evaluate markers associated with liver scarring. By identifying the progression of MASH, this diagnostic data provides clinicians with a non-invasive tool to monitor disease status. Novo, which received FDA accelerated approval for Wegovy for MASH treatment in August 2025, intends to leverage these diagnostics to improve care pathways.
Timeline
In 2021, the FDA granted de novo clearance to the Enhanced Liver Fibrosis test.
In August 2025, Wegovy received FDA accelerated approval for the treatment of MASH.
In September 2026, Novo officially dropped Nordisk from its name.
Health Landscape
This effort shifts liver care toward non-invasive diagnostic integration, moving away from a reliance on traditional biopsy-based assessments. It follows the regulatory path established by the FDA's 2021 de novo clearance to incorporate objective blood-based testing into chronic liver disease management.
If you are managing MASLD or MASH, discuss with your physician whether non-invasive blood-based testing is appropriate for monitoring your liver health. These diagnostic tests can provide clearer data for treatment decisions compared to traditional assessment methods.
The takeaway
The intersection of diagnostic screening and new therapeutic approvals is changing how liver conditions are managed in the U.S. Ask your primary care provider or specialist about current non-invasive testing options available for monitoring liver fibrosis progression.
Further reading
Learn more about the latest innovations in Diabetes care and management.
Live Poll
Do you believe medical companies should prioritize blood tests over traditional biopsy for early diagnosis?
